| 2016-10-06 08:10:48|
ABBV, NBIX 08:10 10/06 10/06/16
AbbVie to present data from two Phase 3 studies on Elagolix for endometriosis
AbbVie (ABBV), in cooperation with Neurocrine Biosciences, (NBIX), will present new data from two replicate Phase 3 studies evaluating the efficacy and safety of Elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, in premenopausal women with endometriosis, at the American Society for Reproductive Medicine Scientific Congress & Expo. Additional data highlighting the economic and healthcare burden associated with endometriosis will also be presented. The presentations will include new results on primary and secondary efficacy and safety from the two Phase 3 studies evaluating the use of Elagolix in endometriosis-associated pain and aAdditional data will be presented on the economic burden of endometriosis and endometriosis-related surgery in women in the U.S.